Renovacor raises $11M to advance gene therapy for rare cardiomyopathy

With backing from its syndicate’s five investors, Renovacor is eyeing an IND submission

With nothing left to prove in an academic setting, five-year-old Renovacor has attracted an $11 million series A round designed to complete preclinical testing of its gene therapy for a rare form of dilated cardiomyopathy.

Novartis Venture Fund, Broadview Ventures and

Read the full 400 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE